Sobi's Board of Directors exercises authority for share repurchase
Sobi announced that its Board of Directors has exercised its authorization to repurchase the company's shares. The action is intended to secure the company's commitments under an incentive program.
Swedish biopharmaceutical company Swedish Orphan Biovitrum AB (publ), known as Sobi, has announced the exercise of its authorization for a share repurchase. The company's Board of Directors has been empowered to buy back shares as part of its strategy to fulfill obligations related to employee incentive programs.
The decision follows a resolution at the Annual General Meeting on May 6, 2026, which granted the Board the authority to repurchase all issued Class C shares. This repurchase will be conducted through an offer directed to all holders of these Class C shares.
Previously, the Annual General Meeting approved a directed issue of up to 223,677 redeemable and convertible Class C shares. The purpose of these actions is to ensure Sobi can meet its commitments under the long-term incentive program, referred to as the All Employee Programme, designed for its permanent employees.
The company aims to secure its obligations concerning employee options and share awards through this repurchase program. Specific details regarding the timeline and terms of the buyback offer have not yet been disclosed.